Compare ASMB & GLAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASMB | GLAD |
|---|---|---|
| Founded | 2005 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.8M | 468.1M |
| IPO Year | 2010 | N/A |
| Metric | ASMB | GLAD |
|---|---|---|
| Price | $27.84 | $20.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $43.40 | $22.33 |
| AVG Volume (30 Days) | 109.9K | ★ 170.6K |
| Earning Date | 11-10-2025 | 02-04-2026 |
| Dividend Yield | N/A | ★ 8.73% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.55 |
| Revenue | $37,191,000.00 | ★ $89,122,000.00 |
| Revenue This Year | $33.33 | $13.52 |
| Revenue Next Year | N/A | $8.34 |
| P/E Ratio | ★ N/A | $8.10 |
| Revenue Growth | ★ 31.30 | N/A |
| 52 Week Low | $7.75 | $18.76 |
| 52 Week High | $39.71 | $30.43 |
| Indicator | ASMB | GLAD |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 47.00 |
| Support Level | $25.93 | $20.70 |
| Resistance Level | $32.31 | $21.20 |
| Average True Range (ATR) | 1.74 | 0.43 |
| MACD | -0.43 | -0.00 |
| Stochastic Oscillator | 25.06 | 46.22 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.